Preclinical Studies Demonstrate a Viable Intravenous Inosine Formulation
and Support Oral Dosing for Three Alseres' DAT Blocker Compounds
HOPKINTON, Mass., March 10 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced that data from preclinical studies of the Company's nerve repair candidate, Inosine, and DAT Blocker product candidates from its neurodegeneration program were presented at the ASENT conference, March 6-8, 2008 in Arlington, VA.
The first poster presentation entitled: "Brain microdialysate and plasma concentrations of Inosine during intravenous Inosine infusion in conscious rats" highlighted the results of a central nervous system (CNS) microdialysis study designed to measure the levels of Inosine in the brain during intravenous infusion of high concentrations of Inosine. The results suggest that Inosine infused intravenously was measurably able to cross the blood- brain barrier. Inosine is a nerve regenerative factor that has been shown to promote axon outgrowth in neurons and has potential to be used to treat CNS disorders such as stroke, spinal cord injury and traumatic brain injury.
"The literature suggests that Inosine can cross the blood-brain
barrier, however, no direct measurements of brain levels of Inosine during
systemic dosing have been previously reported," commented Noel Cusack,
Ph.D, Alseres' Senior Vice President of Preclinical Development. "This
study shows that when administered intravenously using our new,
highly-concentrated Inosine formulation, Inosine levels in the brain
increased more than 600%,
|SOURCE Alseres Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved